Adjusted for covariates , fenofibrate reduced total cardiovascular outcomes ( cardiovascular death , fatal and non-fatal stroke and carotid and coronary revascularisation ) by 30 % in women ( 95 % CI 8 % , 46 % ; p = 0.008 ) and 13 % in men ( 95 % CI -1 % , 24 % ; p = 0.07 ) with no treatment-by-sex interaction ( p > 0.1 ) .